Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025. The announcement will be made via a live video webcast at 8:00 a.m. ET.
KT-621 targets STAT6, a key transcription factor driving Th2 inflammation through IL-4/IL-13 signaling. By degrading STAT6, KT-621 could offer the convenience of an oral therapy with efficacy comparable to injectable biologics, potentially transforming care for over 130 million people worldwide affected by Th2-driven diseases such as atopic dermatitis, asthma, COPD, and more.
A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague.
Preclinical studies indicate KT-621 has demonstrated safety and biologics-like activity, positioning it as a potential game-changer for patients seeking alternatives to injections. The drug is currently being evaluated in a Phase 1b trial for atopic dermatitis, with results expected later this year.
Kymera Therapeutics, Inc. plans to launch Phase 2b trials in atopic dermatitis and asthma by early 2026, aiming to accelerate development across multiple indications.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
